A Look At Sherwin-Williams (SHW) Valuation After Strong Q1 2026 Sales And Data Center Coatings Push

Sherwin-Williams (SHW) is back in focus after reporting Q1 2026 sales that exceeded guidance across all three segments, along with fresh data center coating launches and renewed attention from both analysts and institutional investors.

See our latest analysis for Sherwin-Williams.

Despite Q1 2026 sales outperforming guidance and fresh interest around its data center coatings, Sherwin-Williams’ recent share price momentum has softened, with the stock down 8.7% on a 1 month share price return and the 1 year total shareholder return down 16.9%, although the 3 year total shareholder return of 32.1% points to a stronger longer-term record.

If this mix of coatings and AI infrastructure themes has your attention, it might be a good moment to broaden your watchlist with 42 AI infrastructure stocks

With SHW trading at US$300.10 alongside an intrinsic value estimate suggesting a discount and a consensus analyst target of US$381.45, investors may need to consider whether this recent pullback represents a genuine opportunity or whether potential future growth is already reflected in the price.

Most Popular Narrative: 22.7% Undervalued

With Sherwin-Williams’ fair value narrative sitting at $388.14 against a last close of $300.10, the current price gap centers on what future earnings and margins could support.

The company's sustained focus on cost control, broad and deep restructuring (doubling annual savings targets to ~$80 million), and disciplined SG&A management is structurally improving fixed cost leverage and expected to yield improved net margins and earnings power as sales volumes recover.

Read the complete narrative. Read the complete narrative.

Curious what has to happen for that higher fair value to stack up? The narrative leans on steady revenue gains, thicker margins, and a premium earnings multiple. The exact mix of those assumptions is where the real story sits.

Result: Fair Value of $388.14 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this hinges on demand not staying weak for longer and on Sherwin-Williams avoiding further margin pressure from supply chain inefficiencies and fixed manufacturing costs.

Find out about the key risks to this Sherwin-Williams narrative.

Another Take: Valuation Through Earnings Multiples

While the fair value narrative and discount to intrinsic value point to upside, the earnings multiple tells a tighter story. Sherwin-Williams trades on a P/E of 28.3x versus 24.9x for the US Chemicals industry and 22.1x for peers, and above a fair ratio of 24.4x that the market could move toward.

That premium can signal confidence in Sherwin-Williams’ earnings quality and forecasts, but it also raises the bar for execution if the share price is already richer than both peers and the fair ratio. For you, the key question is whether that extra multiple feels earned or exposed to a reset.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

The mix of upside potential and clear risks might feel finely balanced. It makes sense to move quickly, review the data, and weigh both sides using the 3 key rewards and 1 important warning sign

Looking for more investment ideas?

If Sherwin-Williams is on your radar, do not stop there: casting a wider net across other opportunities can help you build a more resilient portfolio.

• Target steadier growth potential by scanning companies with strong cash flows and attractive prices using the 50 high quality undervalued stocks.
• Boost your income stream by reviewing stocks that combine higher yields with resilient payouts through the 12 dividend fortresses.
• Strengthen your downside protection by focusing on businesses with sturdy finances and low risk profiles via the 66 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com